Literature DB >> 23070159

Stability of colistimethate sodium in aqueous solution.

A M Healan1, W Gray, E J Fuchs, J M Griffiss, R A Salata, J Blumer.   

Abstract

Colistimethate sodium, increasingly used to treat multidrug-resistant Gram-negative infections, spontaneously hydrolyzes to form colistin A (polymyxin E1) and B (polymyxin E2/B) when mixed with water. High levels of these active breakdown products at the time of administration have been associated with nephrotoxicity and even death. In this study, reconstituted colistimethate sodium was shown to be stable (<1.0% colistin A/B formation) for up to 24 h when stored at 21, 0, -20, and -70°C.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23070159      PMCID: PMC3497204          DOI: 10.1128/AAC.01079-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  9 in total

1.  Consensus summary of aerosolized antimicrobial agents: application of guideline criteria. Insights from the Society of Infectious Diseases Pharmacists.

Authors:  Jennifer Le; Elizabeth Dodds Ashley; Melinda M Neuhauser; Jack Brown; Chris Gentry; Michael E Klepser; Ann Marie Marr; Daryl Schiller; Joshua N Schwiesow; Sally Tice; Heather L VandenBussche; G Christopher Wood
Journal:  Pharmacotherapy       Date:  2010-06       Impact factor: 4.705

2.  Stability of colistin methanesulfonate in pharmaceutical products and solutions for administration to patients.

Authors:  Stephanie J Wallace; Jian Li; Craig R Rayner; Kingsley Coulthard; Roger L Nation
Journal:  Antimicrob Agents Chemother       Date:  2008-07-07       Impact factor: 5.191

3.  The pharmacokinetics of colistin in patients with cystic fibrosis.

Authors:  M D Reed; R C Stern; M A O'Riordan; J L Blumer
Journal:  J Clin Pharmacol       Date:  2001-06       Impact factor: 3.126

Review 4.  Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing.

Authors:  Lauren M Lim; Neang Ly; Dana Anderson; Jenny C Yang; Laurie Macander; Anthony Jarkowski; Alan Forrest; Jurgen B Bulitta; Brian T Tsuji
Journal:  Pharmacotherapy       Date:  2010-12       Impact factor: 4.705

Review 5.  Inhaled anti-infective agents: emphasis on colistin.

Authors:  A Michalopoulos; E Papadakis
Journal:  Infection       Date:  2010-02-27       Impact factor: 3.553

6.  Evaluating the stability of colistin and colistin methanesulphonate in human plasma under different conditions of storage.

Authors:  Rajesh V Dudhani; Roger L Nation; Jian Li
Journal:  J Antimicrob Chemother       Date:  2010-04-22       Impact factor: 5.790

7.  Nephrotoxicity associated with the use of intravenous colistin.

Authors:  Cecilia Santamaría; Analia Mykietiuk; Elena Temporiti; Martin E Stryjewski; Fabian Herrera; Pablo Bonvehi
Journal:  Scand J Infect Dis       Date:  2009

8.  Stability of colistin and colistin methanesulfonate in aqueous media and plasma as determined by high-performance liquid chromatography.

Authors:  Jian Li; Robert W Milne; Roger L Nation; John D Turnidge; Kingsley Coulthard
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

9.  Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis.

Authors:  Jian Li; Kingsley Coulthard; Robert Milne; Roger L Nation; Steven Conway; Daniel Peckham; Christine Etherington; John Turnidge
Journal:  J Antimicrob Chemother       Date:  2003-10-29       Impact factor: 5.790

  9 in total
  1 in total

1.  A physicochemical assessment of the thermal stability of dextrin-colistin conjugates.

Authors:  Emilie Chiron; Mathieu Varache; Joana Stokniene; David W Thomas; Elaine L Ferguson
Journal:  Sci Rep       Date:  2021-05-19       Impact factor: 4.379

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.